IRX Therapeutics is a clinical-stage bio-pharmaceutical company developing immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor microenvironment, restoring immune function, and activating a coordinated immune response against the tumor.
The company's lead product candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Studies indicate that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors. It is a primary cell-derived biologic produced by stimulation of human peripheral blood mononuclear cells (PBMCs) obtained from healthy donor whole blood.
IRX-2 is being studied in an ongoing Phase 2B clinical trial in patients with newly diagnosed stage II, III, and IV squamous cell carcinoma of the head and neck and in preoperative early stage breast cancer.
In November 2018, IRX Therapeutics was acquired by Brooklyn ImmunoTherapeutics.
VP of Business Development
President & CEO
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics
IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®
ImmunID & IRX Therapeutics
Documentaries, videos and podcasts